{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:44:05Z","timestamp":1790304245552,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejps.2024.106749","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T12:22:20Z","timestamp":1710591740000},"page":"106749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pharmacokinetics, safety, and tolerability of the novel tetrameric gadolinium-based MRI contrast agent gadoquatrane in healthy Chinese and Japanese men: Two randomized dose-escalation studies including concentration\u2013QTc modeling"],"prefix":"10.1016","volume":"196","author":[{"given":"Xuemei","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-0667","authenticated-orcid":false,"given":"Yubin","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte Maria","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejps.2024.106749_bib0001","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3348\/kjr.2018.0356","article-title":"Gadolinium Deposition in the Brain: current Updates","volume":"20","author":"Choi","year":"2019","journal-title":"Korea. J. Radiol."},{"issue":"3","key":"10.1016\/j.ejps.2024.106749_bib0002","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1148\/radiol.2021211401","article-title":"Gadolinium retention: what do we know?","volume":"301","author":"Cl\u00e9ment","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.ejps.2024.106749_bib0003","series-title":"Prescribing Information","year":"2022"},{"key":"10.1016\/j.ejps.2024.106749_bib0004","series-title":"Summary of Product Characteristics","year":"2023"},{"issue":"3","key":"10.1016\/j.ejps.2024.106749_bib0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"3","key":"10.1016\/j.ejps.2024.106749_bib0006","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10928-017-9565-6","article-title":"Correction to: scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"7","key":"10.1016\/j.ejps.2024.106749_bib0007","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(17)30158-8","article-title":"Gadolinium deposition in the brain: summary of evidence and recommendations","volume":"16","author":"Gulani","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejps.2024.106749_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/RLI.0000000000000947","article-title":"Contrast agent dose reduction in MRI utilizing a generative adversarial network in an exploratory animal study","author":"Haubold","year":"2023","journal-title":"Invest. Radiol."},{"issue":"2","key":"10.1016\/j.ejps.2024.106749_bib0009","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/RLI.0000000000001043","article-title":"Pharmacokinetics, safety, and tolerability of the novel tetrameric, high-relaxivity, macrocyclic gadolinium-based contrast agent gadoquatrane in healthy adults","volume":"59","author":"Hofmann","year":"2024","journal-title":"Invest. Radiol."},{"issue":"1","key":"10.1016\/j.ejps.2024.106749_bib0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12880-021-00600-9","article-title":"Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study","volume":"21","author":"Jakobsen","year":"2021","journal-title":"BMC Med. Imaging"},{"key":"10.1016\/j.ejps.2024.106749_bib0011","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int. Suppl."},{"issue":"10","key":"10.1016\/j.ejps.2024.106749_bib0012","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/RLI.0000000000000583","article-title":"Can virtual contrast enhancement in brain mri replace gadolinium? a feasibility study","volume":"54","author":"Kleesiek","year":"2019","journal-title":"Invest. Radiol."},{"issue":"8","key":"10.1016\/j.ejps.2024.106749_bib0013","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00004424-199008000-00010","article-title":"Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers","volume":"25","author":"Le Mignon","year":"1990","journal-title":"Invest. Radiol."},{"issue":"9","key":"10.1016\/j.ejps.2024.106749_bib0014","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"10","key":"10.1016\/j.ejps.2024.106749_bib0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/RLI.0000000000000889","article-title":"Preclinical profile of gadoquatrane: a novel tetrameric, macrocyclic high relaxivity gadolinium-based contrast agent","volume":"57","author":"Lohrke","year":"2022","journal-title":"Invest. Radiol."},{"issue":"6","key":"10.1016\/j.ejps.2024.106749_bib0016","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am. J. Kid. Dis."},{"issue":"4","key":"10.1016\/j.ejps.2024.106749_bib0017","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.mric.2020.06.001","article-title":"MR imaging safety considerations of gadolinium-based contrast agents: gadolinium retention and nephrogenic systemic fibrosis","volume":"28","author":"McDonald","year":"2020","journal-title":"Magn. Reson. Imaging Clin. N. Am."},{"issue":"2","key":"10.1016\/j.ejps.2024.106749_bib0018","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1148\/radiol.2018181151","article-title":"Gadolinium retention: a research roadmap from the 2018 NIH\/ACR\/RSNA Workshop on Gadolinium Chelates","volume":"289","author":"McDonald","year":"2018","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.ejps.2024.106749_bib0019","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/RLI.0000000000000454","article-title":"Advocating the development of next-generation high-relaxivity gadolinium chelates for clinical magnetic resonance","volume":"53","author":"Runge","year":"2018","journal-title":"Invest. Radiol."},{"issue":"7","key":"10.1016\/j.ejps.2024.106749_bib0020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00004424-199407000-00008","article-title":"Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers","volume":"29","author":"Staks","year":"1994","journal-title":"Invest. Radiol."},{"issue":"3","key":"10.1016\/j.ejps.2024.106749_bib0021","first-page":"249","article-title":"Gadolinium deposition: a study review","volume":"92","author":"Strickler","year":"2021","journal-title":"Radiol. Technol."},{"issue":"1","key":"10.1016\/j.ejps.2024.106749_bib0022","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1148\/radiol.2019192113","article-title":"Next-generation MRI contrast agents: still including gadolinium","volume":"294","author":"Tweedle","year":"2020","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ejps.2024.106749_bib0023","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/RLI.0000000000000725","article-title":"Alternatives to gadolinium-based contrast agents","volume":"56","author":"Tweedle","year":"2021","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.ejps.2024.106749_bib0024","series-title":"Guidance For Industry - E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential For Non-Antiarrhythmic Drugs: October 2005 - ICH","year":"2005"},{"key":"10.1016\/j.ejps.2024.106749_bib0025","series-title":"E14 Clinical evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential For Non-Antiarrhythmic Drugs \u2014 Questions and Answers (R3). Guidance for industry: June 2017, ICH, Revision 2","year":"2017"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T13:35:55Z","timestamp":1717853755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":25,"alternative-id":["S0928098724000605"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106749","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, safety, and tolerability of the novel tetrameric gadolinium-based MRI contrast agent gadoquatrane in healthy Chinese and Japanese men: Two randomized dose-escalation studies including concentration\u2013QTc modeling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106749"}}